StreetInsider.com News Articles

Telomir raises $5.6M in PIPE financing with DeJoria adding $1M

Tue, 06 Oct 2026 08:06:02 -0400

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) has completed an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of common stock, the clinical-stage biotechnology company announced in a press release.

The company issued 4,843,300 shares of common stock at $1.16 per share, representing a 5% discount to the applicable 10-day volume-weighted average price (VWAP). The financing included no accompanying investor warrants, convertible securities, or variable-price or reset features. Alexander Capital, L.P. acted as placement agent.

The financing includes a $1.0 million investment from John Paul DeJoria, co-founder of John Paul Mitchell Systems and Patrón Spirits, who is an existing

Form 8-K Telomir Pharmaceuticals, For: Oct 05

Tue, 06 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261006/27152195.html

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

Tue, 06 Oct 2026 08:00:00 -0400

Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC)

MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of common stock, without any accompanying investor warrants or convertible securities.

The financing includes an additional $1.0 million investment from billionaire entrepreneur and existing significant shareholder John Paul DeJoria, co-founder of John Paul Mitchell

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

Tue, 06 Oct 2026 08:00:00 -0400

Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC)

The financing includes an additional $1.0 million investment from billionaire entrepreneur and existing significant shareholder John Paul DeJoria, co-founder of John Paul Mitchell

Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

Tue, 29 Sep 2026 03:30:00 -0400

In matched Cleveland Clinic and Jewish General Hospital samples, blood-based TELO enumeration detected circulating plasma cells in all Adaptive clonoSEQ-positive cases reviewed and in a series of clonoSEQ-negative or non-evaluable samples; previously reported EuroFlow comparison data are also summarized.

Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on three-dimensional analysis of telomeres (which are the ends of chromosomes), today reported additional clinical research results from its TELO-MRD program for multiple myeloma, including a comparison of blood-based TELO

Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

Tue, 29 Sep 2026 03:30:00 -0400

Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

Tue, 29 Sep 2026 03:30:00 -0400

Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

Tue, 29 Sep 2026 03:30:00 -0400

Telomir-Zn shows retinal benefits in preclinical AMD study

Thu, 17 Sep 2026 08:32:55 -0400

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) announced the peer-reviewed publication of preclinical research showing that its compound Telomir-Zn improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a zebrafish model of age-related macular degeneration (AMD).

The study, published in the International Journal of Molecular Sciences, found that after 14 days of oral treatment, Telomir-Zn improved central visual response, moving-object tracking, and adaptation to light intensity changes. Histological analysis showed restoration of thickness across multiple retinal layers, including the outer and inner nuclear layers, outer plexiform layer, and ganglion cell layer.

Telomir-Zn also reduced brain reactive oxygen species used as a

Form 8-K Telomir Pharmaceuticals, For: Sep 17

Thu, 17 Sep 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260917/27073242.html

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

Thu, 17 Sep 2026 08:30:00 -0400

Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its Metal-Dependent Epigenetic Biology

MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD).

The findings extend the scientific understanding of Telomir-Zn beyond oncology, providing new evidence that modulation of intracellular metal homeostasis may influence disease-associated pathways across substantially different

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

Thu, 17 Sep 2026 08:30:00 -0400

Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its Metal-Dependent Epigenetic Biology

Maxim Group Starts Telomir Pharma (TELO) at Buy

Thu, 17 Sep 2026 07:46:14 -0400

Maxim Group analyst Jason McCarthy initiates coverage on Telomir Pharma (NASDAQ: TELO) with a Buy rating and a price target of $4.00.

For an analyst ratings summary and ratings history on Telomir Pharma click here. For more ratings news on Telomir Pharma click here.

Shares of Telomir Pharma closed at $1.13 yesterday.

Form 8-K Telomir Pharmaceuticals, For: Sep 11

Wed, 16 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260916/27070684.html

Telo Genomics reports blood-based myeloma test outdetects bone marrow method

Tue, 15 Sep 2026 06:32:18 -0400

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) reported clinical research results showing its blood-based TELO-MRD assay detected residual myeloma cells in a higher proportion of matched samples than a standard bone-marrow test in a University of Athens comparison.

Among 42 evaluable matched samples, the company's TeloView-based TELO-MRD assay detected circulating myeloma cells in 39 of 42 samples (92.9%), compared with 23 of 42 samples (54.8%) detected by bone-marrow EuroFlow next-generation flow cytometry. TELO-MRD was positive in 17 of 19 samples that tested negative by the bone-marrow method. The difference was statistically significant (McNemar P=0.000145). The study authors noted the findings require

Telo Genomics reports blood-based myeloma test outdetects bone marrow method

Tue, 15 Sep 2026 06:32:18 -0400

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Tue, 15 Sep 2026 06:30:00 -0400

Proprietary TeloView® blood-based TELO-MRD assay detected residual myeloma cells in a higher proportion of matched samples than bone-marrow next-generation flow cytometry in a University of Athens comparison.

Vancouver, British Columbia--(Newsfile Corp. - September 15, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on three-dimensional analysis of telomeres (which are the ends of chromosomes), today reported clinical research results from its TELO-MRD program in multiple myeloma.

TELO-MRD is a new liquid-biopsy approach to Minimal Residual Disease (MRD) testing. It combines enumeration

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Tue, 15 Sep 2026 06:30:00 -0400

TELO-MRD is a new liquid-biopsy approach to Minimal Residual Disease (MRD) testing. It combines enumeration

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Tue, 15 Sep 2026 06:30:00 -0400

TELO-MRD is a new liquid-biopsy approach to Minimal Residual Disease (MRD) testing. It combines enumeration

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Tue, 15 Sep 2026 06:30:00 -0400

TELO-MRD is a new liquid-biopsy approach to Minimal Residual Disease (MRD) testing. It combines enumeration

Form 8-K Telomir Pharmaceuticals, For: Sep 14

Mon, 14 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260914/27055677.html

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Mon, 14 Sep 2026 08:00:00 -0400

Preclinical Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site Initiation

MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models. The findings establish a translational foundation for evaluating the compound in a naturally occurring disease setting while the company's TNBC program simultaneously advances toward site initiation and Phase 1/2 patient enrollment.

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Mon, 14 Sep 2026 08:00:00 -0400

Preclinical Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site Initiation

Form DEFA14A Telomir Pharmaceuticals,

Wed, 19 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26947261.html

Form DEFA14A Telomir Pharmaceuticals,

Wed, 19 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26947261.html